Optimal management of HCC today (and tomorrow)

Pierre Nahon

Service d'Hépatologie - Hôpital Jean Verdier - Bondy - Université Paris 13 INSERM 1162 - Paris 5 - Génomique fonctionnelle des tumeurs solides








• Abbvie, Astra Zeneca, Bayer, BMS, Gilead, Ipsen, Roche



Optimization goals differ according to tumour burden







- MVI
- Macro-trabecular subtype
- Molecular classification (?)

For many years, physicians were reluctant to perform HCC biopsy



Should we biopsy each liver mass suspicious for HCC before liver transplantation?-No, please don't


Indeterminate 1-2-cm Nodules Found on Hepatocellular Carcinoma Surveillance: Biopsy for All, Some, or None?

Biopsy for Liver Cancer: How to Balance Research Needs With Evidence-Based Clinical Practice


Prognostic molecular signatures

On biopsies

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study




A five-gene transcriptomic hepatic signature including angiopoietin-2 (*ANGPT2*), delta-like ligand 4 (*DLL4*), neuropilin (NRP)/tolloid (TLL)-like 2 (*NETO2*), endothelial cell-specific molecule-1 (*ESM1*), and nuclear receptor subfamily 4, group A, member 1 (*NR4A1*) identifies with high sensitivity and specificity rapidly growing HCCs.





Nault JC, Gastroenterology 2013

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification



Calderaro J. J Hep 2017





Nahon P, Liver Int 2020

Ablation or resection ?

	Ablation	Resection	
2 or 3 nodules	Distant	Same segment	
Localization	Deep	Superficial	
Liver function	Goodª	Excellent ^b	
Portal Hypertension	Yes	Νο	
Mortality	0.3%	1%	
5-yrs survival	76% in patients eligible for resection	75%	

a Malades appartenant principalement à la classe A ou B de Child-Pugh


b Malades appartenant principalement à la classe A de Child-Pugh.avec bilirubine normale et sans hypertension portale


Review




Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations


Jean-Charles Nault^{1,2,3,*,†}, Olivier Sutter⁴, Pierre Nahon^{1,2,3}, Nathalie Ganne-Carrié^{1,2,3}, Olivier Séror^{2,3,4,*}







Monopolar RFA







Monopolar RFA







Monopolar RFA







Monopolar RFA







Monopolar RFA






















32 patients (tremelimumab and ablation at D36)




Several trials in adjuvant setting, with immune checkpoint inhibitors, are ongoing for patients with high risk of recurrence after curative treatment of HCC

Phase	e III Trial	Experimental Arm	Control Arm	Primary endpoint	Secondary endpoints	Planned participant recruitment
	Mate 9 DX 03383458)	Nivolumab	Placebo	Recurrence-free survival	Overall survival Time to recurrence	530
	OTE-937 03867084)	Pembrolizumab	Placebo	Recurrence-free survival overall survival	Adverse event QoL	950
EMR/ (NCT)	ALD 2 03847428)	Durvalumab Bevacizumab	Placebo	Recurrence-free survival	Overall survival Time to recurrence	888
	ave050 04102098)	Atezolizumab Bevacizumab	Active surveillance	Recurrence-free survival	Overall survival Time to recurrence	662

Optimization goals differ according to tumour burden






A broader therapeutic landscape with 5 approved systemic therapies


> Villanueva A, NEJM 2019

How to choose in 2020?


Advanced stage (BCLC stage C: portal invasion and/or extrahepatic spread) Intermediate stage (BCLC stage B: multinodular) progressing upon locoregional therapies



Can we implement tumour genomics in decision making process?




HCC genetic landscape




Schultze K, Nat Genet 2015

But most genetic mutations are not targetable...



...only 20-30% are.



Immunotherapy, N (%)	
Anti-CTLA-4 monotherapy	
Anti-PD/PD-L1 monotherapy	
Anti-PD-1/PD-L1 + immune checkpoint inhibitor	5
+ Anti-CTLA-4	1
+ Anti-LAG3	2
+ Anti-KIR	2






Figure 2.

Genomic determinants of response to sorafenib in patients with advanced HCC. **A**, Months of treatment (y-axis) for each patient annotated with gene alteration and objective response. **B**, Kaplen-Meier (FFS on sorafenib thesp) for patients with PBK-mTOR-activated tumos (V = 12) vesus non-PBK-mTOR tumos (V = 67), demonstrating shorter FFS in PBK-mTOR activated HCCs. **C**, Kaplan-Meier OS on first-line sonfenib therapy for patients with PBK-mTORadivated tumors (V = 12) vesus non-PBK-mTOR tumors (V = 67), demonstrating a shorter OS in PBK-mTOR-activated HCCs.



Harding JJ, Clin Cancer Res 2019

Perspectives : towards more complex associations and strategies



- Small HCC biopsy reveals prognostic information useful to refine therapeutic strategy
- Technological advances in surgery/ablation allow safe curative option in a broader range of patients
- Adjuvant strategies using Immunotherapy are promising to maintain long-term remission in patients with high-risk of recurrence
- Molecular biomakers/signatures associated with antitumoural response will be key when considering the growing number of approved molecules

Sequential biobanking has become pivotal in academic and industrial trials